Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1737119 | 0.98 | EPHX2 (0.58) | EPHX2ADRB1HTR1ASLC6A2HTR2C | |
| SCHEMBL28203428 | 0.83 | HSD11B1 (0.54) | — | |
| SCHEMBL31348096 | 0.83 | HSD11B1 (0.54) | — | |
| SCHEMBL11545649 | 0.82 | HTR1A (0.68) | EPHX2ADRB1HTR1ASLC6A2HTR2C | |
| SCHEMBL30980825 | 0.81 | CYP1A2 (0.56) | — | |
| SCHEMBL3559872 | 0.80 | HSD11B1 (0.51) | — | |
| SCHEMBL10495676 | 0.80 | HTR2C (0.68) | EPHX2ADRB1HTR1ASLC6A2HTR2C | |
| SCHEMBL3683806 | 0.79 | HTR2C (0.61) | EPHX2ADRB1HTR2C | |
| SCHEMBL18740245 | 0.79 | EPHX2 (0.59) | EPHX2HTR1AHTR2CKDM4EALDH1A1 | |
| SCHEMBL1758382 | 0.79 | EPHX2 (0.64) | EPHX2HTR1ASLC6A2HTR2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4268814-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2023-11-01 | — | — | EP | claimed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| EP-4268814-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2023-11-01 | — | — | EP | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5578596-A | TREATMENT OF SEROTONERGIC NEURON RELATED DISEASES, MOTION SICKNESS, ANXIXETY, DEPRESSION | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0668276-A1 | 2-ALKOXY-5,6,7,8-TETRAHYDROQUINOXALINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-08-23 | — | — | EP | disclosed |
| EP-0376633-B1 | Benzoxazepine derivatives | SUNTORY LTD (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5071845-A | Psychotropic or anxyiolytic agent | SUNTORY LIMITED (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0200968-B1 | SUCCINIMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0376633-A2 | Benzoxazepine derivatives | SUNTORY LIMITED (JP) | 1990-07-04 | — | — | EP | disclosed |
| US-4843078-A | ANXIOLYTIC AGENTS | SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | EPHX2 475/4885ADRB1 292/4885HTR1A 3719/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | EPHX2 489/4885ADRB1 280/4885HTR1A 3701/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | EPHX2 513/4885ADRB1 302/4885HTR1A 3598/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | EPHX2 2525/4885ADRB1 2760/4885HTR1A 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.